PuSH - Publikationsserver des Helmholtz Zentrums München

26 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Kellerer, C.* et al.: COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort. Respir. Med. 185:106461 (2021)
2.
Kahnert, K.* et al.: Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET. Respir. Med. 172:106117 (2020)
3.
Kirchberger, I. et al.: The lived experience with pulmonary embolism: A qualitative study using focus groups. Respir. Med. 167:105978 (2020)
4.
Kirsch, F. et al.: Effect of BMI on health care expenditures stratified by COPD GOLD severity grades: Results from the LQ-DMP study. Respir. Med. 175:106194 (2020)
5.
Lutter, J. et al.: Utilization and determinants of use of non-pharmacological interventions in COPD: Results of the COSYCONET cohort. Respir. Med. 171:106087 (2020)
6.
Carsin, A.E.* et al.: Restrictive spirometry pattern is associated with low physical activity levels. A population based international study. Respir. Med. 146, 116-123 (2019)
7.
Frank, A.L. ; Kreuter, M.* & Schwarzkopf, L.: Economic burden of incident interstitial lung disease (ILD) and the impact of comorbidity on costs of care. Respir. Med. 152, 25-31 (2019)
8.
Marietta von Siemens, S.* et al.: CAT score single item analysis in patients with COPD: Results from COSYCONET. Respir. Med. 159:105810 (2019)
9.
Alter, P.* et al.: Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir. Med. 137, 14-22 (2018)
10.
Kahnert, K.* et al.: The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir. Med. 134, 79-85 (2018)
11.
Matthes, S.* et al.: Asthma features in severe COPD: Identifying treatable traits. Respir. Med. 145, 89-94 (2018)
12.
Karch, A.* et al.: The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir. Med. 114, 27-37 (2016)
13.
Schwarzkopf, L. et al.: Impact of chronic ischemic heart disease on the health care costs of COPD patients – An analysis of German claims data. Respir. Med. 118, 112-118 (2016)
14.
Wacker, M. et al.: Direct and indirect costs of COPD and its comorbidities: Results from the German COSYCONET study. Respir. Med. 111, 39-46 (2016)
15.
Burns, J.* et al.: Asthma prevalence in Olympic summer athletes and the general population: An analysis of three European countries. Respir. Med. 109, 813-820 (2015)
16.
Rottenkolber, M.* et al.: Inhaled beta-2-agonists/muscarinic antagonists and acute myocardial infarction in COPD patients. Respir. Med. 108, 1075-1090 (2014)
17.
Menn, P. et al.: Direct medical costs of COPD - an excess cost approach based on two population-based studies. Respir. Med. 106, 540-548 (2012)
18.
Karrasch, S.* et al.: Exhaled nitric oxide and influencing factors in a random population sample. Respir. Med. 105, 713-718 (2011)
19.
Koch, B.* et al.: Lung function reference values in different German populations. Respir. Med. 105, 352-362 (2011)
20.
Meyer, T.* et al.: Effects of formoterol and tiotropium bromide on mucus clearance in patients with COPD. Respir. Med. 105, 900-906 (2011)